EL7.AI
StocksMediumUpdated•Originally published 12 November 2026•Updated 12 November 2026•
1 min read

Taysha Gene Therapies Reports Narrower-Than-Expected Q3 2026 Loss

Key Facts

1Taysha Gene Therapies reported a GAAP EPS of -$0.10, beating analyst estimates by $0.03.

Taysha Gene Therapies reported a GAAP loss per share of $0.10 for the third quarter of 2026. Seeking Alpha reported that these results beat analyst estimates by $0.03, as the company outperformed market expectations for the period.

TSHA shares closed at $4.28 on November 11, 2026, after reaching a session high of $4.32 and a low of $4.18. According to the company, it held $422.8 million in cash and cash equivalents as of September 30, 2026, which is expected to support planned operating expenses and capital requirements into the second half of 2028.

Latest Updates · 1

  1. Notable·

    Update: Taysha's research and development expenses rose to $28.8 million in the third quarter of 2026. This figure represents an increase from the $25.7 million reported in the prior-year period, according to the company's financial results.

Open on chart